# Crysvita (burosumab-twza)

Member and Medication Information	
* indicates required field	
*Member ID:	*Member Name:
*DOB:	*Weight:
*Medication Name/Strength:	Do Not Substitute. Authorizations will be processed for
the preferred Generic/Brand equivalent unless specified. *Directions for use:	
Provider Information	
* indicates re	
*Requesting Provider Name:	*NPI:
*Address:	
*Contact Person:	*Phone #:
*Fax #:	Email:
Medically Billed Information	
* indicates required field for all medically billed products	
*Diagnosis Code:	*HCPCS Code:
*Dosing Frequency:	*HCPCS Units per dose:
Servicing Provider Name:	NPI:
Servicing Provider Address:	
Facility/Clinic Name:	NPI:
Facility/Clinic Address:	
Fax form and relevant documentation including: laboratory results, chart notes and/or updated provider letter to Pharmacy PA at <b>855-828-4992</b> , to prevent processing delays.	

## **Criteria for Approval:** (*ALL* of the following criteria must be met)

- Medication is prescribed by or in consultation with a physician who specializes in the disease treatment
- □ The provider attests that if used concurrent, oral phosphates and/or active vitamin D analogs will be discontinued 1 week prior to treatment initiation.
- □ Patient does not have severe renal impairment or end stage renal disease.
- Patient does not have normal/above normal serum phosphate ranges for age.
  Sale of applicables
- Select applicable:
- Diagnosis of X-linked hypophosphatemia (XLH) (All must be met)
  - The patient is at least 6 months of age and older
  - **The diagnosis was confirmed by genetic testing for mutations in the** *PHEX* **gene on the** X **chromosome.**
  - □ Lab results of low blood levels phosphorus and high levels of the hormone FGF23, demonstrating persistent hypophosphatemia
- Diagnosis of tumor-induced osteomalacia (All must be met)
  - The patient is at least 2 years of age and older
  - $\hfill\square$  The provider has determined that the tumor cannot be identified or completely resected

### **Re-authorization Criteria:**

Updated letter with medical justification or updated chart notes demonstrating positive clinical response.

**Initial Authorization:** Up to six (6) months **Re-authorization:** Up to one (1) year

#### UTAH MEDICAID PHARMACY PRIOR AUTHORIZATION REQUEST FORM

Note: Use appropriate HCPCS code for billing

- Coverage and Reimbursement code look up: <u>https://health.utah.gov/stplan/lookup/CoverageLookup.php</u>
- HCPCS NDC Crosswalk: https://health.utah.gov/stplan/lookup/FeeScheduleDownload.php

#### **PROVIDER CERTIFICATION**

I hereby certify this treatment is indicated, necessary and meets the guidelines for use.

Prescriber's Signature

Date